Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Darnell

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Cancers|July 14, 2023
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric PredictionSergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, et al.
Gastroenterologia Y Hepatologia|December 3, 2014
[Assessment and treatment of acute pancreatitis. Position document of the Catalan Society of Gastroenterology, Catalan Society of Surgery and Catalan Society of the Pancreas]Jaume Boadas, Joaquin Balsells, Juli Busquets, et al.
United European Gastroenterology Journal|July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
Hepatology (Baltimore, Md.)|September 13, 2017
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse eventsJordi Rimola, Álvaro Díaz-González, Anna Darnell, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trialsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
Journal of Hepatology|July 18, 2020
Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosisMarta Magaz, Alberto Alvarez-Larrán, Dolors Colomer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological responseMattias Mandorfer, Fanny Turon, Sabela Lens, et al.
Journal of Hepatology|September 4, 2022
Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosisAnna Baiges, Bogdan Procopet, Gilberto Silva-Junior, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Cancers|July 14, 2023
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric PredictionSergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, et al.
Gastroenterologia Y Hepatologia|December 3, 2014
[Assessment and treatment of acute pancreatitis. Position document of the Catalan Society of Gastroenterology, Catalan Society of Surgery and Catalan Society of the Pancreas]Jaume Boadas, Joaquin Balsells, Juli Busquets, et al.
United European Gastroenterology Journal|July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
Hepatology (Baltimore, Md.)|September 13, 2017
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse eventsJordi Rimola, Álvaro Díaz-González, Anna Darnell, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trialsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
Journal of Hepatology|July 18, 2020
Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosisMarta Magaz, Alberto Alvarez-Larrán, Dolors Colomer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological responseMattias Mandorfer, Fanny Turon, Sabela Lens, et al.
Journal of Hepatology|September 4, 2022
Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosisAnna Baiges, Bogdan Procopet, Gilberto Silva-Junior, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Pageof 6